fasudil has been researched along with Granulocytic Leukemia, Chronic in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burthem, J | 1 |
| Rees-Unwin, K | 1 |
| Mottram, R | 1 |
| Adams, J | 1 |
| Lucas, GS | 1 |
| Spooncer, E | 1 |
| Whetton, AD | 1 |
1 other study available for fasudil and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antigens, CD34; Benzamides; Cell Proliferatio | 2007 |